Effects of antiglaucoma drops on MMP and TIMP balance in conjunctival and subconjunctival tissue

Investigative Ophthalmology and Visual Science

Volumn 47, Issue 3, 2006, Pages 823-830

  Ito, Tadashi ^a   Ohguro, Hiroshi ^a   Mamiya, Kazuhisa ^a   Ohguro, Ikuyo ^a   Nakazawa, Mitsuru ^a  

^a HIROSAKI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIGLAUCOMA AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL; BRIMONIDINE; BUNAZOSIN; CARTEOLOL; COLLAGENASE; LATANOPROST; LEVOBUNOLOL; MATRIX METALLOPROTEINASE; NIPRADILOL; PROSTAGLANDIN DERIVATIVE; STROMELYSIN; TIMOLOL; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 3; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIHYPERTENSIVE AGENT; EYE DROPS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONJUNCTIVA; CONTROLLED STUDY; CORNEA; CORNEA CELL; DOWN REGULATION; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; EXTRACELLULAR MATRIX; FIBROBLAST; GLAUCOMA; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; INTRAOCULAR PRESSURE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RAT; UPREGULATION; ZYMOGRAPHY; ANIMAL; CELL CULTURE; ENZYMOLOGY; METABOLISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPRAGUE DAWLEY RAT; TOPICAL DRUG ADMINISTRATION; WESTERN BLOTTING;

ADMINISTRATION, TOPICAL; ADRENERGIC ALPHA-AGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ADRENERGIC BETA-ANTAGONISTS; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOTTING, WESTERN; CELLS, CULTURED; CONJUNCTIVA; CORNEA; EXTRACELLULAR MATRIX; FIBROBLASTS; GLAUCOMA; MATRIX METALLOPROTEINASES; OPHTHALMIC SOLUTIONS; PROSTAGLANDINS, SYNTHETIC; RATS; RATS, SPRAGUE-DAWLEY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TISSUE INHIBITOR OF METALLOPROTEINASES; UP-REGULATION;

EID: 33645410523     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.05-0902     Document Type: Article

References (67)

1. Shields MB, Ritch R, Krupin T. Classifications of the glaucomas. In: Ritch R, Shields MB, Krupin T, eds. The Glaucomas. St. Louis: CV Mosby; 1996;717-725.
2. Kerrigan LA, Zack DJ, Quigley HA, Smith SD, Pease ME. TUNEL-positive ganglion cells in human primary open-angle glaucoma. Arch Ophthalmol. 1997;116:993-1001.
3. Okisaka S, Murakami A, Mizukawa A, Ito J. Apoptosis in retinal ganglion cell decrease in human glaucomatous eyes. Jpn J Ophthalmol. 1997;41:84-88.
4. Quigley HA, Nickells RW, Kerrigan LA, Pease ME, Thibault DJ, Zack DJ. Retinal ganglion cell death in experimental glaucoma and after axotomy occurs by apoptosis. Invest Ophthalmol Vis Sci. 1995;36:774-786.
5. Garcia-Valenzuela E, Shareef S, Walsh J, Sharma SC. Programmed cell death of retinal ganglion cells during experimental glaucoma. Exp Eye Res. 1995;61:33-44.
6. Levin LA, Louhab A. Apoptosis of retinal ganglion cells in anterior ischemic optic neuropathy. Arch Ophthalmol. 1996;114:488-491.
7. Neufeld AH, Hernandes R, Gonzalez M. Nitric oxide synthase in the human glaucomatous optic nerve head. Arch Ophthalmol. 1997;115:479-503.
8. Dreyer EB, Zurakowski D, Schumer RA, Podos SM, Lipton SA. Elevated glutamate levels in the vitreous body of humans and monkeys with glaucoma. Arch Ophthalmol. 1997;114:299-305.
9. Romano C, Barrett DA, Li Z, Pestronk A, Wax MB. Anti-rhodopsin antibodies in sera from patients with normal-pressure glaucoma. Invest Ophthalmol Vis Sci. 1995;36:1968-1975.
10. Wax MB, Tezel G, Saito I, et al. Anti-Ro/SS-A positivity and heat shock protein antibodies in patients with normal-pressure glaucoma. Am J Ophthalmol. 1998;125:145-157.
11. Tezel G, Seigel GM, Wax MB. Autoantibodies to small heat shock proteins in glaucoma. Invest Ophthalmol Vis Sci. 1998;39:2277-2287.
12. Maruyama I, Maeda T, Okisaka S, Mizukawa A, Ohguro H. Autoantibody against neuron-specific enolase found in glaucoma patients cause retinal dysfunction in vivo. Jpn J Ophthalmol. 2002;46:1-12.
13. Collaborative Normal-Tension Glaucoma Study Group. Comparison of glaucomatous progression between untreated patients with normal tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol. 1998;126:487-497.
14. Collaborative Normal-Tension Glaucoma Study Group. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am J Ophthalmol. 1998;126:498-505.
15. Hernandez MR, Gong H. Extracellular matrix of the trabecular meshwork and optic nerve head. In: Ritch R, Shields MB, Krupin T, eds. The Glaucomas. St. Louis: Mosby; 1996:213-249.
16. Madlener M, Parks WC, Werner S. Matrix metalloproteinases (MMPs) and their physiological inhibitors (TIMPs) are differentially expressed during excisional skin wound repair. Exp Cell Res. 1998;242:201-210.
17. Moses MA, Marikovsky M, Harper JW, et al. Temporal study of the activity of matrix metalloproteinases and their endogenous inhibitors during wound healing. J Cell Biochem. 1996;60:379-386.
18. Shapiro SD. Matrix metalloproteinase degradation of extracellular matrix: biological consequences. Curr Opin Cell Biol. 1998;10:602-608.
19. Kon CH, Occleston NL, Charteris D, Daniels J, Aylward GW, Khaw PT. A prospective study of matrix metalloproteinases in proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci. 1998;39:1524-1529.
20. Tamiya S, Wormstone IM, Marcantonio JM, Gavrilovic J, Duncan G. Induction of matrix metalloproteinases 2 and 9 following stress to the lens. Exp Eye Res. 2000;71:591-597.
21. Dishku N, John MK, Schultz GS, Reid TW. Pterigia pathogenesis: corneal invasion by matrix metalloproteinase expressing altered limbal epithelial basal cells. Arch Ophthalomol. 2001;119:695-706.
22. Schlotzer-Schrehardt U, Lommatzsch J, Kuchle M, Konstas AG, Naumann GO. Matrix metalloproteinases and their inhibitors in aqueous humor of patients with pseudoexfoliation syndrome/glaucoma and primary open-angle glaucoma. Invest Ophthalmol Vis Sci. 2003;44:1117-1125.
23. Addicks EM, Quigley HA, Green WR, Robin AL. Histologic characteristics of filtering blebs in glaucomatous eyes. Arch Ophthalmol. 1983;101:795-798.
24. Jampel HD, McGuidan LJB, Dunkelberger GR, L'Hernault NL, Quigley HA. Cellular proliferation after experimental glaucoma filtration surgery. Arch Ophthalmol. 1988;106:89-94.
25. Li DQ, Meller D, Liu Y, Tseng SCG. Overexpression of MMP-1 and MMP-3 by cultured conjunctivochalasis fibroblasts. Invest Ophthalmol Vis Sci. 2000;41:404-410.
26. Mamiya K, Ohguro H, Ohguro I, et al. Effects of matrix metalloproteinase-3 gene transfer by electroporation in glaucoma filter surgery. Exp Eye Res. 2004;79:405-410.
27. Honjo M, Tanihara H, Kido N, Inatani M, Okazaki K, Honda Y. Expression of ciliary neurotrophic factor activated by retinal Muller cells in eyes with NMDA- and kainic acid-induced neuronal death. Invest Ophthalmol Vis Sci. 2000;41:552-560.
28. Lam TT, Abler AS, Kwong JMK, Tso MOM. N-methyl-D-aspartate (NMDA)-induced apoptosis in rat retina. Invest Ophthalmol Vis Sci. 1999;40:2391-2397.
29. Siliprandi R, Canella R, Carmingnoto G, et al. N-methyl-D aspartate induced neurotoxicity in the adult rat retina. Vis Neurosci. 1992;8:567-573.
30. Steuhl KP, Knor M, Frohn A, Thiel HJ. The influence of topically applied anti-glaucomatous eye drops on conjunctival cell differentiation. Fortscher Ophthalmol. 1991;88:865-869.
31. Schwab IR, Linberg JV, Gioia VM, Benson WH, Chao GM. Foreshortening of the inferior fornix associated with chronic glaucoma medications. Ophthalmology. 1992;99:197-202.
32. Broadway DC, Grierson I, O'Brien C, Hitchings RA. Adverse effects of topical anti-glaucoma medication, I: the conjunctival cell profile. Arch Ophthalmol. 1994;112:1437-1445.
33. Broadway DC, Grierson I, Hitchings RA. Adverse effects of topical anti-glaucoma medication on the conjunctiva. Br J Ophthalmol. 1993;77:590-596.
34. Broadway DC, Grierson I, Hitchings RA. The effect of topical anti-glaucomatous medications on the cell profile of the conjunctiva. Curr Opin Ophthalmol. 1993;4:51-57.
35. Trope GE, Liu GS, Basu PK. Toxic effects of topically administrated betagan, betoptic and timoptic on regenerating corneal epithelium. J Ocul Pharmacol. 1988;4:359-366.
36. Herras JM, Pastor JC, Calonge M, Asensio VM. Ocular surface alteration after long-term treatment with an anti-glaucoma drug. Ophthalmology. 1992;99:1082-1088.
37. Williams DE, Nguyen KD, Shapourifar-Tehrani S, Kitada S, Lee DA. Effects of timolol, betaxolol, and levobunolol on human Tenon's fibroblasts tissue culture. Invest Ophthalmol Vis Sci. 1992;33:2233-2241.
38. Mietz H, Niesen U, Krieglstein GK. Histopathologic changes in the conjunctiva after chronic application of anti-glaucoma drugs with and without preservatives. Graefes Arch Clin Exp Ophthalmol. 1994;232:561-565.
39. 2α-isopropylester treatment. Arch Ophthalmol. 2001;119:1165-1170.
40. Mietz H, Schlotzer-Schrehardt U, Strassfeld C, Krieglstein GK. Effect of latanoprost and timolol on the histopathology of rabbit conjunctiva. Invest Ophthalmol Vis Sci. 2001;42:679-687.
41. Parks WC, Mecham RP. Matrix Metalloproteinases. San Diego: Academic Press; 1998.
42. Gomez DE, Alonso DF, Yoshiji H, Thorgeirsson UP. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol. 1997;74:111-122.
43. Ruhul AAR, Senga T, Oo ML, Thant AA, Hamaguchi M. Secretion of matrix metalloproteinase-9 by the proinflammatory cytokine, IL-1beta: a role for the dual signalling pathways, Akt and Erk. Genes Cell. 2003;8:515-523.
44. Hantke B, Harbeck N, Schmalfeldt B, et al. Clinical relevance of matrix metalloproteinase-13 determined with a new highly specific and sensitive ELISA in ascitic fluid of advanced ovarian carcinoma patients. Biol Chem. 2003;384:1247-1251.
45. Brehmer B, Biesterfeld S, Jakse G. Expression of matrix metalloproteinases (MMP-2 and -9) and their inhibitors (TIMP-1 and -2) in prostate cancer tissue. Prostate Cancer Prostatic Dis. 2003;6:217-222.
46. Wilson EM, Moainie SL, Baskin JM, et al. Region- and type-specific induction of matrix metalloproteinases in post-myocardial infarction remodeling. Circulation. 2003;107:2857-2863.
47. Nagai R. Cardiovascular research in the era of genome medicine and EBM. Rinsho Byori. 2003;51:208-213.
48. Power C, Henry S, Del Bigio MR, et al. Intracerebral hemorrhage induces macrophage activation and matrix metalloproteinases. Ann Neurol. 2003;53:731-742.
49. Rosenberg GA. Matrix metalloproteinases in neuroinflammation (erratum). Glia. 2002;40:130.
50. Haung SH, Admis AP, Wiederschain DG, Shima DT, Shing Y, Moses MA. Matrix metalloproteinases and heir inhibitors in aqueous humor. Exp Eye Res. 1996;62:481-490.
51. Gonzales-Avila G, Gineba M, Hayakawa T, Vadillo-Ortega F, Teran L, Selman M. Collagen metabolism in human aqueous humor from primary open-angle glaucoma: decreased degradation and increased biosynthesis play a role in its pathogenesis. Arch Ophthalmol. 1995;113:1319-1323.
52. Agapova OA, Ricard CS, Salvador-Silva M, Hernadez MR. Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human optic nerve head astrocyte. Glia. 2001;33:205-216.
53. Yan X, Tezel G, Wax MB, Edward DP. Matrix metalloproteinases and tumor necrosis factor α in glaucomatous optic nerve head. Arch Ophthalmol. 2000;118:666-673.
54. Jampel HD, McGuidan LJB, Dunkelberger GR, L'Hernault NL, Quigley HA. Cellular proliferation after experimental glaucoma filtration surgery. Arch Ophthalmol. 1988;116:89-94.
55. Kitazawa Y, Suemori-Matsushita H, Yamamoto T, Kawase K. Lowdose and high-dose mitomycin trabeculectomy as an initial surgery in primary open-angle glaucoma. Ophthalmology. 1993;100:1624-1628.
56. Khaw PT, Sherwood MB, MacKay SL, Rossi MJ, Schltz G. Five-minute treatments with fluorouracil, floxuridine, and mitomycin have long-term effects on human tenon's capsule fibroblasts. Arch Ophthalmol. 1992;110:1150-1154.
57. Nuyts RM, Felten PC, Pels E, et al. Histopathologic effects of mitomycin C after trabeculectomy in human glaucomatous eyes with persistent hypotony. Am J Ophthalmol. 1994;118:225-237.
58. Shin DH, Iskander NG, Ahee JA, et al. Long-term filtration and visual field outcomes after primary glaucoma triple procedure with and without mitomycin-C. Ophthalmology. 2002;109:1607-1611.
59. Katz GJ, Higginbotham EJ, Lichter PR, et al. Mitomycin C versus 5-fluorouracil in high-risk glaucoma filtering surgery: extended follow-up. Ophthalmology. 1995;102:1263-1269.
60. Kitazawa Y, Kawase K, Matsushita H, Minobe M. Trabeculectomy with mitomycin: a comparative study with fluorouracil. Arch Ophthalmol. 1991;109:1693-1698.
61. Shields MB, Scroggs MW, Sloop CM, Simmons RB. Clinical and histopathologic observations concerning hypotony after trabeculectomy with adjunctive mitomycin C. Am J Ophthalmol. 1993;116:673-683.
62. Gandolfi SA, Vecchi M, Braccio L. Decrease of intraocular pressure after subconjunctival injection of mitomycin in human glaucoma. Arch Ophthalmol. 1995;113:582-585.
63. WAF-1/Cip-1 to prevent wound healing in a rabbit model of glaucoma filtration surgery. Arch Ophthalmol. 2002;120:941-949.
64. Sakamoto T, Oshima Y, Sakamoto M, et al. Electroporation and bleomycin in glaucoma-filtering surgery. Invest Ophthalmol Vis Sci. 1997;38:2864-2868.
65. Heller LC, Coppola D. Electrically mediated delivery of vector plasmid DNA elicits an antitumor effect. Gene Ther. 2002;9:1321-1325.
66. Lucas ML, Heller L, Coppola D, Heller R. IL-12 plasmid delivery by in vivo electroporation for the successful treatment of established subcutaneous B16.F10 melanoma. Mol Ther. 2002;5:668-675.
67. Rols MP, Bachaud JM, Giraud P, Chevreau C, Roche H, Teissie J. Electrochemotherapy of cutaneous metastases in malignant melanoma. Melanoma Res. 2000;10:468-474.